Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

This activity was originally broadcast in conjunction with AMCP 2025. This activity includes animation videos.

Program Description

There have been significant advancements in the management of multiple myeloma (MM), leading to improved survival rates. However, relapse remains an inevitable part of the disease course. Novel treatment approaches, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), have emerged as effective treatment modalities for relapsed or refractory disease, though these therapies are associated with significant toxicities and operational barriers that complicate their use. Managed care pharmacists play a crucial role in developing utilization protocols aimed to reduce operational barriers, resolve administration challenges, and optimize resource utilization. This session will examine the most recent clinical evidence and guideline recommendations for the use of BsAbs and ADCs in the treatment of relapsed/refractory MM to prepare managed care professionals to design workflows that reduce barriers to access to these treatments and ensure appropriate resource allocation.

Target audience: Managed care pharmacists, oncology pharmacists

Type of activity: Application
Release date: April 9, 2025
Expiration date: April 9, 2026

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate the mechanisms and nuances between antibody-drug conjugates (ADCs) and bispecific antibody (BsAb) therapies that drive treatment decisions for the use in multiple myeloma (MM).
• Dissect the recent clinical data of antibody-based regimens in the treatment of MM.
• Compare the guideline-recommended use of BsAbs and ADCs in the treatment of relapsed/refractory MM.
• Investigate operational strategies to optimize access and safety of antibody-based regimens in the treatment of relapsed/refractory MM.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-077-H01-P. The activity is available for CE credit through April 9, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following financial relationships with commercial interests to disclose:
Consultant: Bristol Myers Squibb, Genentech, Genmab A/S, Pfizer, Sanofi.

James A. Davis, PharmD, BCOP, has the following financial relationships with a commercial interest to disclose:
Consultant: Janssen Biotech; Speakers Bureau: Janssen Biotech.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms